Bioptimus announces a $76M funding milestone, with the latest injection of $41M led by Cathay Innovation less than 12 months from its initial seed round Since the successful release of the largest AI foundation model for pathology in July, the company has been continuing its groundbreaking work and is now poised to release a breakthrough […]
Licensing agreement gives Elevation Oncology access to Synaffix’s ADC technology for one program in combination with SYNstatin E™ Elevation Oncology nominates a novel HER3 ADC candidate EO-1022 leveraging its antibody as well as Synaffix’s proprietary ADC development technologies AMSTERDAM, THE NETHERLANDS, 12 December 2024 — Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its […]
Enable Medicine is at the forefront of using generative AI models to search vast cellular atlases of disease to discover new therapeutic insights Partnership will greatly boost the two companies’ drug discovery and development capabilities It comes after their first collaboration that led to Ennovate Pharma SAS, working on highly promising targets in autoimmune and […]
Optimum Client’s Win Big at LSX European Lifestars Awards! Congratulations to Optimum’s clients – Asceneuron SA, Calliditas Therapeutics, DISCO Pharmaceuticals GmbH, Sofinnova Partners portfolio company Moon Surgical, Myricx Bio, and Novo Holdings, all of whom took home LSX European Lifestars awards! Plus, a special moment for Optimum’s Zoe Bolt who presented the award for Private […]
Paris, France – November 18th, 2024 – BrightHeart, a leading AI innovator in obstetric and pediatric cardiology technology, announces it has received FDA 510(k) clearance for its first artificial intelligence software, designed to transform prenatal ultrasound evaluations of the fetal heart. This milestone marks a significant breakthrough in one of the most challenging and critical […]
